Generic Medicine Info
May be taken with or without food. May be taken w/ meals to minimise GI irritation.
Severe toxic CNS depression, comatose states, Parkinson's disease, basal ganglia lesions, thyrotoxicosis, significant cardiac disorders (e.g. acute MI, uncompensated heart failure, arrhythmias, clinically significant bradycardia, 2nd or 3rd degree heart block, uncorrected hypokalaemia). Lactation.
Special Precautions
Patient with dementia-related psychosis, bipolar disorders, seizures or EEG abnormalities, risk of falls, risk of QT prolongation, risk factors for stroke, severe CV disease, decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problems, and narrow angle glaucoma. Concomitant use with antidepressants and anticholinergic agents. Avoid abrupt withdrawal. Renal and hepatic impairment. Elderly. Children. Pregnancy. Patient Counselling This drug may cause somnolence, if affected, do not drive or operate machinery. Avoid exposure to extreme heat. Avoid strenuous exercise. Ensure adequate fluid intake to prevent dehydration. Monitoring Parameters Monitor mental status, CBC, electrolytes balance, ECG, liver function, serum glucose and HbA1c level, hemorrhage, abnormal involuntary movements or parkinsonian signs, visual changes.
Adverse Reactions
Significant: Extrapyramidal syndrome (e.g. pseudoparkinsonism, akathisia, tardive dyskinesia, dystonia), CNS depression, anticholinergic effects (e.g. constipation, xerostomia, blurred vision, urinary retention), esophageal dysmotility and aspiration, somnolence, orthostatic hypotension, motor or sensory instability, hyperprolactinaemia. Cardiac disorders: Cardiac arrhythmia, tachycardia. Eye disorders: Visual disturbance. Gastrointestinal disorders: Diarrhoea, nausea, sialorrhoea, vomiting. General disorders and administration site conditions: Injection site reaction. Hepatobiliary disorders: Jaundice. Metabolism and nutrition disorders: Anorexia, hypoglycaemia. Nervous system disorders: Agitation, restlessness, headache. Psychiatric disorders: Confusion, depression, insomnia. Renal and urinary disorders: Urinary retention. Reproductive system and breast disorders: Erectile dysfunction, gynaecomastia, priapism. Respiratory, thoracic and mediastinal disorders: Bronchospasm, dyspnoea. Skin and subcutaneous tissue disorders: Acneiform rash, maculopapular rash. Vascular disorders: Hypotension.
Potentially Fatal: Neuroleptic malignant syndrome, bronchopneumonia, blood dyscrasias (e.g. leucopenia, neutropenia, agranulocytosis), QT prolongation, torsade de pointes.
Drug Interactions
Altered concentration of haloperidol with CYP3A4 and CYP2D6 inhibitors and inducers. May increase plasma concentration of tricyclic antidepressant.
CIMS Class
ATC Classification
N05AD01 - haloperidol ; Belongs to the class of butyrophenone derivatives antipsychotics.
Disclaimer: This information is independently developed by CIMS based on haloperidol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in